17 November 2003 15:53 [Source: ICIS news]
LONDON (CNI)--AstraZenca announced Monday it had received approval under Europe’s mutual recognition procedure to offer a higher dose range of its Symbicort Turbuhaler drug to some patients with persistent asthma.
Under the higher dosing regime, patients will be allowed to use the drug in up to four inhalations twice-daily in strengths of 80/4.5 micrograms and 160/4.5 micrograms, which are already approved in Canada, Switzerland, New Zealand and Mexico.
In the European Union (EU), national licences are expected to be issued over the next few months. The EU countries are Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden and the UK.
Once national licences are granted, prescribers and patients will have a wider range of Symbicort dosing options.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections